Brentwood, Tenn., March 3, 2009-Praxis, a company specializing in centralized patient recruitment for clinical research studies, will provide patient recruitment services to a major pharmaceutical company for a national study on the Hepatitis C Virus. The study explores an investigational drug’s effectiveness as a mono-treatment as well as an add-on treatment option for the condition affecting almost 4 million Americans.
According to a report issued by the Center for Disease Control, top notable factors and/or behaviors increase the possibility that someone will contract HCV include:
“There are over 50 trails testing different medical solutions for HCV…over 50. That in conjunction with other difficulty factors shows the immense need for a focused & strategic recruitment effort. We are excited to be partnering on this trial offering customized, executable solutions that will help the sponsor achieve the desired results.” David Fox, Praxis President & CEO adds, “This is also a new partnership for us and we are thrilled to be here and confident in our experience, research and execution strategy put in place that we will see this trail to success.”
Praxis Communications, Inc., headquartered in Brentwood, Tenn., provides the pharmaceutical and biotech industries with a wide range of global services for patient recruitment and retention for clinical trials including patient profiling, recruitment planning, centralized fulfillment, media relations, advertising, and program management. For more information, call Praxis at (615) 312-8207 or visit www.GoPraxis.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.